Methods and compositions to inhibit adverse effects associated with vaccinations
The invention relates to methods of inhibiting side effects associated with vaccination in a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject before the subject is vaccinated, wherein the pharmaceutical composition comprises: a) a non-steroidal anti-inflammatory drug (NSAID); and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine and cetirizine and combinations thereof.
1. A method of inhibiting side effects associated with vaccination in a human subject in need thereof, comprising:
administering an effective amount of a pharmaceutical composition to the subject before the subject is vaccinated, wherein the pharmaceutical composition comprises:
a) a non-steroidal anti-inflammatory drug (NSAID); and
b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine and cetirizine and combinations thereof;
wherein the side effects associated with the vaccination are inhibited in the human subject.
2. The method of claim 1 wherein the NSAID is selected from the group consisting of: aspirin, ibuprofen, naproxen, diclofenac, diflunisal, etodolac, indomethacin, ketoprofen, ketorolac, meloxicam, nabumetone, oxaprozin, piroxicam, salsalate, sulindac, and tolmetin.
3. The method of claim 2 wherein the NSAID is naproxen sodium and the co-agent is fexofenadine.
4. The method of claim 3 wherein the amount of naproxen sodium is about 220 mg to about 880 mg, and the amount of fexofenadine is about 60 mg to about 180 mg.
5. The method of claim 4 wherein the naproxen sodium and the fexofenadine are combined in one unit dose.
6. The method of claim 4 wherein the naproxen sodium and the fexofenadine is in the form of a tablet, lozenge or chewing gum.
7. The method of claim 1 wherein the pharmaceutical composition is administered daily beginning at most 24 hours before administration of an influenza vaccine.
8. The method of claim 1 wherein the vaccine is an influenza vaccine.
9. The method of claim 1 wherein the side effects include injection site soreness, congestion, coughing, fever, and/or muscle/joint pain.
10. The method of claim 1 wherein the amount of ibuprofen is about 200 mg to about 800 mg.
11. The method of claim 1 wherein the amount of aspirin is about 325 mg to about 1000 mg.
12. The method of claim 1 wherein the amount of ketotifen is about 0.5 mg to about 3 mg.
13. The method of claim 1 wherein the amount of desloratidine is about 5 mg to about 10 mg.
14. A method of inhibiting the side effects associated with the administration of an influenza vaccine in a human subject in need thereof, comprising:
administering to the subject an effective amount of a pharmaceutical composition prior to administration of an influenza vaccine, wherein the pharmaceutical composition consists essentially of:
a) about 220 mg to about 880 mg of naproxen sodium, and
b) about 60 mg to about 180 mg fexofenadine,
wherein the side effects associated with the administration of an influenza vaccine are inhibited in the human subject.
15. A method of inhibiting side effects associated with vaccination in a human subject in need thereof, comprising:
administering an effective amount of a pharmaceutical composition to the subject within about 48 after the subject is vaccinated, wherein the pharmaceutical composition comprises:
a) a non-steroidal anti-inflammatory drug (NSAID); and
b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, cetirizine and combinations thereof;
wherein the side effects associated with the vaccination are inhibited in the human subject.